China's Delays In Approving Clinical Trials, Poor IP Protections Block Access To Innovative Drugs - EU Chamber Of Commerce
This article was originally published in The Pink Sheet Daily
Executive Summary
Excellent clinical trial centers and a good medical infrastructure make China well-qualified to better integrate global clinical trials, increase cooperation with world-class clinicians and speed up the regulatory process, according to an EU Chamber position paper.